tulisokibart

AssetAlso PRA-023

Monoclonal antibody targeting TL1A (TNFSF15) to inhibit inflammation and fibrosis.

Stage: Phase 2
Modality: Antibody
Target: Inflammation; 2
Indications: 0
Trials: 1
Developer

Indications

2

Hidradenitis suppurativa
Phase 2, pmlive.com, 1 Oct 2026
Moderate to severe hidradenitis suppurativa
Phase 2, pmlive.com, 1 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Evidence for its targets2
Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.